Background: Vandetanib is a clinically approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of medullary thyroid cancer. The gene discussed is EGFR; the disease is medullary thyroid gland carcinoma.